NCT06295029View on ClinicalTrials.gov

Personalized Medication Software for BCL-2 Inhibitor in AML Patients Using Machine Learning and Genomics

Not yet recruitingOBSERVATIONAL

Enrollment

200

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Acute Myeloid Leukemia

All Listed Sponsors

lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

NCT06295029 - Personalized Medication Software for BCL-2 Inhibitor in AML Patients Using Machine Learning and Genomics | Biotech Hunter | Biotech Hunter